Abstract 973P
Background
Fibrolamellar carcinoma (FLC) is a rare subtype of liver cancer that primarily affects young adults and adolescents. The main objective of this study is to evaluate the association between survival outcomes and clinical factors of patients with FLC.
Methods
We retrospectively collected clinicopathologic and treatment outcome data from 88 male and 77 female patients with a pathologic diagnosis of FLC. Median overall survival (OS) was calculated using Kaplan-Meier curves. Log rank test, univariable and multivariable Cox models were applied to evaluate the association between clinical outcomes and patients’ characteristics.
Results
Mean age at diagnosis was 27.4 years (age range: 9, 76), median OS was 42.6 months (95% CI: 36.5, 59.2). 50.3% of patients in our study were AJCC Stage IV at the time of presentation, with 67.5% having vascular invasion at diagnosis. 5% of patients had liver cirrhosis. 68.5% of patients received surgery, including metastasectomy. 30.9% received radiation therapy, and 77.5% received systemic therapy. Combination of 5-fluorouracil and interferon-alpha2 was the most frequently used systemic therapy (83 patients), with 45 patients receiving other forms of chemotherapy. The median OS of patients who underwent surgery was 59.2 months (95% CI [49.51, 89.68]) versus 20.34 months (95% CI [15.37, 26.02] in patients who did not. Of those who did not have surgery, 94.2% (49 patients) had AJCC stage >II. Higher tumor stage(>II) (HR=2.841; 95% CI [1.309, 6.165]), lack of surgery (HR=3.47; 95% CI [2.193, 5.488]) and lack of receipt of radiation therapy (HR=1.685; 95% CI [1.059, 2.68]) were positively associated with worse OS.
Conclusions
We identified prognostic factors in FLC. The associations of receipt of surgery and radiation with prolonged OS suggest that local control and cancer debulking in this disease is paramount.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
946P - Sintilimab plus lenvatinib as conversion therapy in patients with unresectable hepatocellular carcinoma: A prospective, non-randomized, open-label, phase II, expansion cohort study
Presenter: Shichun Lu
Session: Poster session 18
947P - The efficacy and safety of cadonilimab combined with lenvatinib for first-line treatment of advanced hepatocellular carcinoma: A phase Ib/II clinical trial
Presenter: Li Bai
Session: Poster session 18
949P - Regorafenib combined with immunotherapy versus regorafenib as second-line therapy in patients with advanced hepatocellular carcinoma: A multicenter real-world study
Presenter: Bin-Kui Li
Session: Poster session 18
952P - Efficacy and safety of a PRospective, Observational trial of Lenvatinib cOmbined with transarterial chemoembolization (TACE) as initial treatment for advaNced staGe hepatocellular carcinoma (PROLONG): A multicenter, single-armed, real-world study
Presenter: Guoliang Shao
Session: Poster session 18
953P - Tislelizumab plus regorafenib as second-line therapy for unresectable hepatocellular carcinoma (uHCC): A single-arm, phase II trial
Presenter: Zhongchao Li
Session: Poster session 18
954P - Radiotherapy combined with tislelizumab plus anlotinib as first-line treatment for hepatocellular carcinoma: A single arm, phase II clinical trial
Presenter: Guishu wu
Session: Poster session 18
955P - IMMUNIB trial (AIO-HEP-0218/ass): A single-arm phase II study evaluating safety and efficacy of immunotherapy with nivolumab in combination with lenvatinib in advanced hepatocellular carcinoma
Presenter: Arndt Vogel
Session: Poster session 18